PCM
PFE icon

Portolan Capital Management’s Pfizer PFE Stock Holding History

Portolan Capital Management’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-164,751
Closed -$5.11M – 153
2020
Q2 		$5.11M Sell
164,751
-97,525
-37% -$3.31M 0.58% 72
2020
Q1 		$8.12M Buy
+262,276
New +$8.94M 1.22% 27

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Portolan Capital Management's PFE Position: Q3 2020 in Review

Portolan Capital Management sold out of Pfizer (PFE) in Q3 2020, closing a stake of 164,751 shares — an estimated $5.11M sold.

Portolan Capital Management first reported a position in PFE in Q1 2020 and held it in 2 quarters. The position peaked at $8.12M in Q1 2020. 2,508 funds tracked by Wall St. Rank hold PFE as of Q3 2020.

  • Portolan Capital Management reported no remaining Pfizer position as of Q3 2020 after selling out during the quarter.
  • Portolan Capital Management sold 164,751 Pfizer shares in Q3 2020, an estimated $5.11M.
  • Portolan Capital Management first reported a position in Pfizer in Q1 2020 and held it in 2 quarters.
  • Portolan Capital Management's Pfizer position peaked at $8.12M in Q1 2020.
  • 2,508 funds tracked by Wall St. Rank held Pfizer as of Q3 2020.

Based on Portolan Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.